Daniel Soffer

1.7k total citations · 2 hit papers
41 papers, 979 citations indexed

About

Daniel Soffer is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Daniel Soffer has authored 41 papers receiving a total of 979 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Surgery, 18 papers in Endocrinology, Diabetes and Metabolism and 13 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Daniel Soffer's work include Lipoproteins and Cardiovascular Health (24 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (15 papers) and Lipid metabolism and disorders (8 papers). Daniel Soffer is often cited by papers focused on Lipoproteins and Cardiovascular Health (24 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (15 papers) and Lipid metabolism and disorders (8 papers). Daniel Soffer collaborates with scholars based in United States, Canada and Pakistan. Daniel Soffer's co-authors include Kevin C. Maki, Karen Aspry, Carol F Kirkpatrick, Geeta Sikand, Penny M. Kris‐Etherton, Daniel J. Rader, Archna Bajaj, Dave L. Dixon, Jesse Chittams and Danielle Duffy and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American College of Cardiology and Neurology.

In The Last Decade

Daniel Soffer

34 papers receiving 955 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force

2019 239 citations Carol F Kirkpatrick, Penny M. Kris‐Etherton et al. Journal of clinical lipidology profile →
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice

2024 127 citations Archna Bajaj, Dave L. Dixon et al. Journal of clinical lipidology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Soffer United States	15	461	421	274	209	151	41	979
Arjan J. Kwakernaak Netherlands	19	233 0.5×	180 0.4×	124 0.5×	185 0.9×	144 1.0×	45	991
Jaimini Cegla United Kingdom	13	462 1.0×	302 0.7×	77 0.3×	153 0.7×	95 0.6×	41	740
Mats Martinell Sweden	19	218 0.5×	460 1.1×	93 0.3×	149 0.7×	158 1.0×	39	815
Tamara Glavinovic Canada	7	295 0.6×	210 0.5×	72 0.3×	169 0.8×	69 0.5×	13	552
Eliana Polisecki United States	17	473 1.0×	229 0.5×	61 0.2×	128 0.6×	163 1.1×	32	829
Carlo Pirazzi Sweden	16	679 1.5×	570 1.4×	385 1.4×	246 1.2×	195 1.3×	29	1.5k
Jonathan Fialkow United States	12	539 1.2×	247 0.6×	105 0.4×	269 1.3×	53 0.4×	29	1.0k
Alaina K. Natoli Australia	8	247 0.5×	338 0.8×	203 0.7×	186 0.9×	132 0.9×	9	767
Melchior C. Nierman Netherlands	15	357 0.8×	325 0.8×	60 0.2×	542 2.6×	218 1.4×	32	1.1k
Philip H. Frost United States	16	408 0.9×	612 1.5×	101 0.4×	400 1.9×	249 1.6×	22	1.2k

Countries citing papers authored by Daniel Soffer

Since Specialization

Citations

This map shows the geographic impact of Daniel Soffer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Soffer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Soffer more than expected).

Fields of papers citing papers by Daniel Soffer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Soffer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Soffer. The network helps show where Daniel Soffer may publish in the future.

Co-authorship network of co-authors of Daniel Soffer

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Soffer. A scholar is included among the top collaborators of Daniel Soffer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Soffer. Daniel Soffer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Soffer, Daniel, et al.. (2025). STATIN-INDUCED NECROTIZING AUTOIMMUNE MYOPATHY COMPLICATED BY RHABDOMYOLYSIS FOLLOWING COVID-19 INFECTION. Journal of the American College of Cardiology. 85(12). 4032–4032.

Kalra, Dinesh, Abhimanyu Garg, P. Barton Duell, et al.. (2025). Lipoprotein X – Pathophysiology, diagnosis, and management. PubMed. 19(4). 759–774.

Soffer, Daniel, et al.. (2024). Using Guidelines of Care to Lower Cardiovascular Risk in Patients with Psoriasis. Dermatologic Clinics. 42(3). 417–428. 4 indexed citations

Bajaj, Archna, et al.. (2024). ASCVD Risk Reduction in Patients with Immune-Mediated Inflammatory Disease: A Retrospective Quality Assessment Study. Journal of clinical lipidology. 18(4). e510–e511. 1 indexed citations

Hegele, Robert A., Zahid Ahmad, Ambika P. Ashraf, et al.. (2024). Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. Journal of clinical lipidology. 19(1). 83–94. 16 indexed citations

Filtz, Annalisa, Andrea Scotti, Juan J. Badimón, et al.. (2024). New approaches to triglyceride reduction: Is there any hope left?. SHILAP Revista de lepidopterología. 18. 100648–100648. 9 indexed citations

Soffer, Daniel, Nicholas Marston, Kevin C. Maki, et al.. (2024). Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. Journal of clinical lipidology. 18(5). e647–e663. 30 indexed citations

Soffer, Daniel, et al.. (2024). Attitudes and barriers to lipoprotein(a) testing: A survey of providers at the University of Pennsylvania Health System. Journal of clinical lipidology. 18(5). e873–e876. 6 indexed citations

Campos, Cynthia, Zahid Ahmad, Ambika P. Ashraf, et al.. (2024). Development of a Clinical Diagnostic Score for Familial Chylomicronemia Syndrome (FCS). Journal of clinical lipidology. 18(4). e536–e536. 3 indexed citations

10.

Burke, Frances, et al.. (2023). Clinical Vignette - Keto Diet-Induced Dyslipidemia and Lean Mass Hyper-Responders. Journal of clinical lipidology. 17(4). e7–e8. 2 indexed citations

11.

Goldberg, Anne C., Daniel Soffer, Christie M. Ballantyne, Martha Gulati, & Michael D. Shapiro. (2023). NLA/ASPC response to the USPSTF recommendation statement on screening lipid panel in children and adolescents. SHILAP Revista de lepidopterología. 17. 100628–100628.

12.

Mszar, Reed, et al.. (2023). Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia. Journal of Clinical Medicine. 12(4). 1382–1382. 8 indexed citations

13.

Soffer, Daniel, Robert M. Stoekenbroek, & Roda Plakogiannis. (2022). Small interfering ribonucleic acid for cholesterol lowering – Inclisiran. Journal of clinical lipidology. 16(5). 574–582. 27 indexed citations

14.

Sampson, Maureen, Rami A. Ballout, Daniel Soffer, et al.. (2021). A new phenotypic classification system for dyslipidemias based on the standard lipid panel. Lipids in Health and Disease. 20(1). 170–170. 11 indexed citations

15.

Hernández, Patricia, et al.. (2021). Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis. Current Atherosclerosis Reports. 23(11). 72–72. 37 indexed citations

16.

Adusumalli, Srinath, et al.. (2019). SCREENING FOR HYPERLIPIDEMIA IN PREGNANT WOMEN: AN UNDERUTILIZED OPPORTUNITY FOR EARLY RISK ASSESSMENT. Journal of the American College of Cardiology. 73(9). 14–14. 9 indexed citations

17.

Pallazola, Vincent A., Vasanth Sathiyakumar, Jihwan Park, et al.. (2019). Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia). Archives of Medical Science. 16(5). 993–1003. 23 indexed citations

18.

Kirkpatrick, Carol F, Penny M. Kris‐Etherton, Geeta Sikand, et al.. (2019). Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force. Journal of clinical lipidology. 13(5). 689–711.e1. 239 indexed citations breakdown →

19.

Baum, Seth J., Daniel Soffer, & P. Barton Duell. (2016). Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia. Reviews in Cardiovascular Medicine. 17(1-2). 16–27. 3 indexed citations

20.

Watson, Catherine E., Lise Kjems, Surya Ayalasomayajula, et al.. (2010). Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. Journal of Lipid Research. 52(2). 361–373. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact